.jpeg)
Analysis of indications for Foscarbidopa/Foscarbidopa for injection
Foscarbidopa/foslevodopa for injection is a drug used to treat specific neurological diseases. Its indications mainly focus on fluctuations in motor symptoms in patients with advanced Parkinson's disease (PD).
Foscarbidopa/Foscarbidopa/Foscarbidopa is approved for the treatment of fluctuating motor symptoms in adults with advanced Parkinson's disease. Parkinson's disease is a chronic, progressive neurological disease characterized by resting tremor, myotonia, bradykinesia and postural balance disorder. As the disease progresses, patients often experience fluctuations in motor symptoms, that is, a sudden increase or decrease in symptoms, which seriously affects the patient's quality of life.
Foscarbidopa/Foscarbidopa/Foscarbidopa is a subcutaneous continuous infusion therapy based on levodopa. After entering the body, foscarbidopa is converted into carbidopa and foscarbidopa is converted into levodopa. Carbidopa can inhibit the peripheral decarboxylation of levodopa and reduce the peripheral metabolism of levodopa, thereby increasing the amount of levodopa entering the brain. Levodopa decarboxylates in the brain to generate dopamine, which supplements the lack of dopamine in the brain of patients with Parkinson's disease, thereby alleviating fluctuations in motor symptoms.
Foscarbidopa is only administered subcutaneously, usually as a continuous infusion via a specialized infusion pump. Patients need to adjust the infusion rate and dose according to their condition and tolerance under the guidance of their doctor. During use, patients need to be closely monitored for adverse reactions, such as injection site reactions, infections, hallucinations, and movement disorders, and corresponding measures must be taken in a timely manner.
Reference: https://www.vyalev.com/
Foscarbidopa/Foscarbidopa/Foscarbidopa is approved for the treatment of fluctuating motor symptoms in adults with advanced Parkinson's disease. Parkinson's disease is a chronic, progressive neurological disease characterized by resting tremor, myotonia, bradykinesia and postural balance disorder. As the disease progresses, patients often experience fluctuations in motor symptoms, that is, a sudden increase or decrease in symptoms, which seriously affects the patient's quality of life.
Foscarbidopa/Foscarbidopa is indicated for the treatment of patients with advanced Parkinson's disease. These patients often respond poorly to traditional oral medications or experience severe fluctuations in motor symptoms.
Foscarbidopa/Foscarbidopa/Foscarbidopa is a subcutaneous continuous infusion therapy based on levodopa. After entering the body, foscarbidopa is converted into carbidopa and foscarbidopa is converted into levodopa. Carbidopa can inhibit the peripheral decarboxylation of levodopa and reduce the peripheral metabolism of levodopa, thereby increasing the amount of levodopa entering the brain. Levodopa decarboxylates in the brain to generate dopamine, which supplements the lack of dopamine in the brain of patients with Parkinson's disease, thereby alleviating fluctuations in motor symptoms.
Foscarbidopa is only administered subcutaneously, usually as a continuous infusion via a specialized infusion pump. Patients need to adjust the infusion rate and dose according to their condition and tolerance under the guidance of their doctor. During use, patients need to be closely monitored for adverse reactions, such as injection site reactions, infections, hallucinations, and movement disorders, and corresponding measures must be taken in a timely manner.
Reference: https://www.vyalev.com/
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
